Evidence map›Paper›PMID 32943631›Full record

ArticleNature communications2020

Author Correction: A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics.

Michael A Crone, Miles Priestman, Marta Ciechonska, Kirsten Jensen, David J Sharp, Arthi Anand, Paul Randell, Marko Storch, Paul S Freemont

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Building Biofoundry India: challenges and path forward.Synthetic biology (Oxford, England) · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Michael A CroneLondon Biofoundry, Imperial College Translation and Innovation Hub, White City Campus, 80 Wood Lane, London, W12 0BZ, UK.ORCID http://orcid.org/0000-0002-5675-0172
Miles PriestmanLondon Biofoundry, Imperial College Translation and Innovation Hub, White City Campus, 80 Wood Lane, London, W12 0BZ, UK.ORCID http://orcid.org/0000-0002-0811-354X
Marta CiechonskaLondon Biofoundry, Imperial College Translation and Innovation Hub, White City Campus, 80 Wood Lane, London, W12 0BZ, UK.ORCID http://orcid.org/0000-0003-1165-6921
Kirsten JensenLondon Biofoundry, Imperial College Translation and Innovation Hub, White City Campus, 80 Wood Lane, London, W12 0BZ, UK.
David J SharpUK Dementia Research Institute Centre for Care Research and Technology, Imperial College London, London, UK.
Arthi AnandHistocompatibility and Immunogenetics Laboratories, Department of Infection and Immunity, North West London Pathology, London, UK.
Paul RandellDepartment of Infection and Immunity, North West London Pathology, London, UK.
Marko StorchLondon Biofoundry, Imperial College Translation and Innovation Hub, White City Campus, 80 Wood Lane, London, W12 0BZ, UK.ORCID http://orcid.org/0000-0003-1503-8282
Paul S FreemontLondon Biofoundry, Imperial College Translation and Innovation Hub, White City Campus, 80 Wood Lane, London, W12 0BZ, UK. p.freemont@imperial.ac.uk.ORCID http://orcid.org/0000-0002-5658-8486

Funding

Biotechnology and Biological Sciences Research Council BB/M025632/1
6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID32943631
PMCPMC7498595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.